The impact of HPV infection on survival in a geographically defined cohort of oropharynx squamous cell carcinoma (OPSCC) patients in whom surgical treatment has been one main treatment

Ljøkjel, Borghild; Lybak, Stein; Haave, Hilde; Olofsson, Jan; Vintermyr, Olav Karsten; Aarstad, Hans Jørgen

doi:10.3109/00016489.2014.886336

Cited by 28 publications

(31 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During recent years, the focus of HPV in head and neck cancer has shifted toward studying HPV mainly in OPSCC [17]. However, accumulating data suggests that also the concept of HPV in OPSCC is too broad and unspecific, especially in relation to when HPV status is utilized as a marker for treatment and clinical outcome [4][5][6][7]10]. The present data are in line with such assumptions and support the notion that HPV infection is highly associated with "lymphoepithelial" tissues.…”

Section: Discussionmentioning

confidence: 99%

Human papillomavirus and survival of patients per histological subsite of tonsillar squamous cell carcinoma

Haeggblom

Attoff

Hammarstedt‐Nordenvall

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Current data advocate that oropharyngeal squamous cell carcinoma (OPSCC) should be divided into subsites when evaluating the presence of human papillomavirus (HPV) and prognosis. More specifically, tonsillar squamous cell carcinoma (TSCC) and base of tongue squamous cell carcinoma (BOTSCC) have much higher HPV prevalence compared to other OPSCC. Moreover, patients with HPV positive (HPV+) TSCC and BOTSCC have a better prognosis as compared to patients with HPV negative (HPV−) corresponding tumors, while the prognostic role of HPV in other OPSCC is unclear. Furthermore, in a recent report from Denmark, TSCC was further subclassified into specified TSCC (STSCC) and nonspecified TSCC (NSTSCC), with HPV significantly more prevalent in STSCC. In this study, the histopathological influence of HPV prevalence and survival in TSCC was analyzed in a TSCC cohort with known HPV status, of patients diagnosed 1970–2002 in Stockholm. In total, 139 TSCC biopsies with both tumor and adjacent normal tissue were separated into STSCC and NSTSCC. HPV was significantly more commonly found in STSCC than in NSTSCC. Patients with HPV+ STSCC had a better disease‐specific and overall survival as compared to patients with HPV+ NSTSCC, but no survival differences were observed in patients with HPV− STSCC and NSTCC. These findings confirm previous reports and suggest that TSCC subsite may also be of relevance for clinical outcome and should be further followed up in future studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Human papillomavirus and survival of patients per histological subsite of tonsillar squamous cell carcinoma

Haeggblom

Attoff

Hammarstedt‐Nordenvall

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Chronic inflammation has also been suggested to promote head and neck squamous cell carcinoma (HNSCC) [4]. Furthermore, the steadily growing knowledge about the human papilloma virus (HPV) as a pathogen of some HNSCC tumors [5], especially the oropharyngeal (OP)SCC [6, 7], should encourage the addressing of inflammation in the development of HNSCC.…”

Section: Introductionmentioning

confidence: 99%

In Vitro-Stimulated IL-6 Monocyte Secretion and In Vivo Peripheral Blood T Lymphocyte Activation Uniquely Predicted 15-Year Survival in Patients with Head and Neck Squamous Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

The study was performed in order to determine whether peripheral blood monocyte in vitro function, and lymphocyte in vivo activation at diagnosis, was associated with HPV tumor infection status and 15-year survival in head and neck squamous cell carcinoma (HNSCC) patients. Sixty-five patients from a consecutive cohort of newly diagnosed HNSCCs, together with 18 control patients, were included in the study. Monocyte responsiveness was assessed by measuring monocyte in vitro interleukin (IL)-6 secretions after 24 hours of LPS stimulation in cultures with a serum-free medium. T lymphocyte activation was determined as the fraction of CD71-positive cells on CD3-positive cells by flow cytometry, whereas HPV infection was determined by PCR on formalin-fixed paraffin-embedded (FFPE) tumor tissue. Disease-specific survivals and overall survivals were determined 15 years following inclusion. HPV-positive HNSCC patients had a lower monocyte LPS-stimulated IL-6 response. A high LPS-stimulated monocyte IL-6 response predicted a decreased survival rate (P=0.019). A high percentage of CD71-positive T lymphocytes also predicted an impaired prognosis (P=0.021). The predictive power of IL-6 monocyte LPS-stimulated responses was retained when adjusted for age, gender and TNM stage of the patients. The monocyte and T lymphocyte survival predictions were independent of each other. The survival was particularly low with a combined high activated monocyte and T lymphocyte status. In a multivariate analysis, IL-6 secretion and the percentage of CD71-positive T lymphocytes both uniquely predicted survival independent of HPV infection status. It is postulated that the natural and adaptive immune systems are separately and additionally linked to the clinical aggressiveness of HNSCCs.

show abstract

“…Similarly, the presence of multiple hr HPV types in a sample was recorded sequentially from the HPV type with the strongest signal/highest viral load (dominant) to the HPV type with the lowest signal for any given HPV type. For samples, in which no definite HPV type were obtained by the f ‐HPV test, an alternative HPV test using the G p 5+/G p 6+ HPV PCR primers and Sanger DNA sequencing was used for hr HPV type identification, as previously reported . The hr HPV DNA type in the latter test was identified using the NCBI BLAST database and regularly >98% sequence homology was recognized for HPV type identity.…”

Section: Methodsmentioning

confidence: 99%

“…The material for HPV (HCII) testing was taken as a separate cervical brush sample normally in parallel with a sample for a cervical Pap smear. The HPV testing was performed on the Hybrid Capture 2 (HCII) HPV DNA test platform (Qiagen, Gaithersburg, MD) during the whole study period and identified the high risk (hr) HPV types 16,18,31,33,35,39,45,51,52,56,58,59 and 68 without any typing. Information on HPV status was routinely not available for the cytotechnicians.…”

Section: Definitionsmentioning

confidence: 99%

“…For samples, in which no definite HPV type were obtained by the f-HPV test, an alternative HPV test using the Gp51/Gp61 HPV PCR primers and Sanger DNA sequencing was used for hrHPV type identification, as previously reported. 31 The hrHPV DNA type in the latter test was identified using the NCBI BLAST database and regularly >98% sequence homology was recognized for HPV type identity. HrHPV type was determined by the fHPV test in 662 samples (88.0%) and by Sanger sequencing in 90 samples (12.0%).…”

Section: Cancer Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Human papillomavirus type specific risk of progression and remission during long‐term follow‐up of equivocal and low‐grade HPV‐positive cervical smears

Vintermyr

Andersland

Bjørge

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

The prevalence of clinically relevant HPV types and their specific risk for progression and regression in women with atypical squamous cells of uncertain significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) were studied in a routine screening population. A 4-year cohort of women (n = 820) with ASCUS/LSIL and a positive HPV test in triage were followed for 6-9 years. The progression risks for CIN2+/CIN3+ were determined for single (71.2%) and multiple HPV infections (28.8%). The CIN2+ progression risk for all HPV 16, all HPV 35, single HPV 16 and single HPV 35 infections were 65.3% (95% CI: 59.6-71.0), 64.4% (95% CI: 50.4-78.4), 63.8% (95% CI: 56.2-71.4) and 73.7% (95% CI: 53.9-93.5), respectively. Based on CIN2+ progression risks four main groups were defined; the HPV 16 group, the HPV 31/33/35 group, the HPV 18/45/51/52 group and the HPV 39/56/58/59/66/68 group with progression risks of 65.3% (95% CI: 59.6-71.0), 62.1% (95% CI: 54.8-69.4), 52.6 (95% CI: 45.9-59.3) and 39.5 (95% CI: 33.0-46.0), respectively. In multivariate analyses, women in the age group 40-49 years had an increased risk of CIN2+ progression. As for CIN3+, HPV 16 had a higher progression risk than other HPV risk groups (p < 0.05). In multiple infections only HPV 16 had a significant additive CIN3+ progression risk (p < 0.05) as compared to other HPV risk groups. In summary, HPV types 16 and 35, including the HPV risk group 31/33/35, had a similar CIN2+ progression risk, but only HPV 16 had a higher risk for CIN3+ progression.

show abstract

The impact of HPV infection on survival in a geographically defined cohort of oropharynx squamous cell carcinoma (OPSCC) patients in whom surgical treatment has been one main treatment

Cited by 28 publications

References 20 publications

Human papillomavirus and survival of patients per histological subsite of tonsillar squamous cell carcinoma

Human papillomavirus and survival of patients per histological subsite of tonsillar squamous cell carcinoma

In Vitro-Stimulated IL-6 Monocyte Secretion and In Vivo Peripheral Blood T Lymphocyte Activation Uniquely Predicted 15-Year Survival in Patients with Head and Neck Squamous Cell Carcinoma

Human papillomavirus type specific risk of progression and remission during long‐term follow‐up of equivocal and low‐grade HPV‐positive cervical smears

Contact Info

Product

Resources

About